ReviewGenes and environment : the official journal of the Japanese Environmental Mutagen Society2026
Multi-omics insights into the mechanisms and prognosis of IPF.
Review in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) represents another progressive and devastating interstitial lung disease found across populations, with a prominent male predominance accounting for approximately 70% of cases. Regional variation in IPF-related genetic polymorphisms, especially in the Americas, Europe, and Asia, points to a hereditary basis. Family history is the main risk factor. Rare mutations may alter outcomes through gene interactions. Environmental factors such as smoking can worsen genetic risk by epigenetic mechanisms like DNA methylation. Unlike studies that focus narrowly on specific genetic variants or processes, this study integrates the genetic variation map, multi-omics regulatory networks, and the effects of environmental exposures in IPF. This links clinical decision-making and gene discovery. This study examines mechanisms, therapies, and prognoses to clarify the impact of epigenetics and genetics on disease development. It also proposes using a multi-gene risk score (MGRS) to predict outcomes and design targeted treatments. The research advances the translation of basic knowledge into therapies. Theoretical and clinical support can aid doctors treating IPF.Clinical trial numberNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.